Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Pacific Biosciences of California, Inc.

Stage 2 · Advancing · week 1

As of Oct 22, 2026, Pacific Biosciences of California is in Stage 2, the uptrend phase, now in its first week (since Oct 16, 2026). It closed at $2.06, 28.2% below its 52-week high and above its 200-day average, which is rising.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. More about the company

$2.06
-3.74% today
$640M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is PACB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 32w
S4 19w
S2 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 1w → S3 6w → S4 12w → S1 6w → S4 32w → S1 3w → S4 2w → S1 8w → S2 4w → S3 5w → S4 19w → S1 10w → S4 4w → S1 1w → S2 17w → S3 6w → S4 10w → S1 4w → S4 3w → S1 1w → S4 7w → S1 2w → S2 1w current
Total tracked: 164 weeks across 23 stage runs.

PACB among Medical Devices40th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…40PACBStage 2 · wk 161+46.1%
vs 52W High
-28.2%
$1.11 lo$2.87 hi
28.2% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 1
1w13w26w
Week 1, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
28.9%
200 DMA: $1.60 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.75x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+46.1%
3M
+51.5%
6M
+31.2%
YTD
+12.0%
1Y
+8.4%
Scan Membership
Breakout Watch
Latest: 2024-12-23
7 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 1 · Vol 0.75x
2026-10-21S2
Wk 1 · Vol 1.12x
2026-10-20S2
Wk 1 · Vol 0.87x
2026-10-19S2
Wk 1 · Vol 0.50x
2026-10-16S21→2
Wk 1 · Vol 0.86x
2026-10-15S1
Wk 2 · Vol 1.05x
2026-10-14S1
Wk 2 · Vol 0.77x
2026-10-13S1
Wk 2 · Vol 1.04x
2026-10-12S1
Wk 2 · Vol 1.04x
2026-10-09S1
Wk 2 · Vol 1.12x
2026-10-08S1
Wk 1 · Vol 2.17x
2026-10-07S1
Wk 1 · Vol 1.88x
Moving averages & range
50 DMA
$1.67
200 DMA
$1.60
52W High
$2.87
52W Low
$1.11
5D Low
$1.73
Resistance levels (recent highs)
20d High
$2.87
60d High
$2.87
120d High
$2.87
250d High
$2.87
Next resistance
+39.3%
to 20d High
ROE
-929.3%
Profit margin -82.5%
Dividend Yield
0.00%
P/B -19.3

Pacific Biosciences of California: quick answers

What stage is Pacific Biosciences of California in?

As of Oct 22, 2026, Pacific Biosciences of California (PACB) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 16, 2026 and is in its first week there. What the four stages mean

Is Pacific Biosciences of California in an uptrend?

Yes. Pacific Biosciences of California is in a Stage 2 uptrend. It trades 28.9% above its 200-day average, which is rising.

How far is Pacific Biosciences of California from its 52-week high?

Pacific Biosciences of California closed at $2.06 on Oct 22, 2026, 28.2% below its 52-week high of $2.87. Its 52-week low is $1.11.

How has Pacific Biosciences of California performed over the past year?

As of Oct 22, 2026, Pacific Biosciences of California is up 8.4% over the past year and up 12.0% so far in 2026.

Which sector and industry is Pacific Biosciences of California in?

Pacific Biosciences of California is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.